Gina treatment of aathma
Reading File
Finding Sources
Finding Sources
Searching the Web
GINA 2025 asthma treatment guidelines stepwise
Finding Sources
Reading Web Page
https://ginasthma.org/wp-content/uploads/2025/11/GINA-Summar…
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative sources. Here is the full GINA treatment overview:
GINA Treatment of Asthma (2025 Update)
GINA (Global Initiative for Asthma) uses a personalized, stepwise approach built around three cyclical actions: Assess - Adjust - Review Response.
Core Principle: Anti-Inflammatory Reliever (AIR)
A major paradigm shift in recent GINA updates: ICS-formoterol (inhaled corticosteroid + formoterol) is now the preferred reliever at all steps, replacing SABA-only (salbutamol) as the default. This is because:
- It reduces the risk of severe exacerbations compared to SABA reliever
- Asthma mortality can occur even in mild/intermittent asthma
- Formoterol has rapid onset, making ICS-formoterol viable as a rescue inhaler
GINA Stepwise Treatment - Adults & Adolescents (≥12 years)
GINA 2025 offers two parallel tracks:
Track 1 (Preferred) - ICS-Formoterol as Reliever
| Step | Preferred Controller | Reliever |
|---|---|---|
| Step 1 | None (AIR only) | As-needed low-dose ICS-formoterol |
| Step 2 | Low-dose ICS, or as-needed ICS-formoterol | As-needed low-dose ICS-formoterol |
| Step 3 | MART* - low-dose ICS-formoterol maintenance | As-needed low-dose ICS-formoterol |
| Step 4 | MART* - medium-dose ICS-formoterol maintenance | As-needed ICS-formoterol |
| Step 5 | High-dose ICS-LABA + add-on therapy | As-needed ICS-formoterol |
*MART = Maintenance And Reliever Therapy
Track 2 (Alternative) - SABA as Reliever
| Step | Preferred Controller | Reliever |
|---|---|---|
| Step 1 | Low-dose ICS taken whenever SABA taken | SABA as needed |
| Step 2 | Low-dose ICS daily, or LTRA | SABA as needed |
| Step 3 | Low-dose ICS-LABA, or medium-dose ICS | SABA as needed |
| Step 4 | Medium-dose ICS-LABA, or high-dose ICS | SABA as needed |
| Step 5 | High-dose ICS-LABA + phenotype assessment | SABA as needed |
Note: Before prescribing Track 2, check whether the patient is likely to adhere to daily controller treatment.
Step 5: Add-On (Biologic) Therapies
At Step 5, refer for phenotypic/endotypic assessment. Biologics are reserved for severe, poorly controlled asthma:
| Biologic | Target | Indication |
|---|---|---|
| Omalizumab | Anti-IgE | Allergic asthma, elevated IgE |
| Mepolizumab / Benralizumab / Reslizumab | Anti-IL-5 / Anti-IL-5R | Eosinophilic asthma (blood eos ≥300/µL) |
| Dupilumab | Anti-IL-4R (blocks IL-4 & IL-13) | Eosinophilic asthma or FeNO ≥20-25 ppb; reduces exacerbations by ≥50% |
| Tezepelumab | Anti-TSLP | Broadest spectrum - works even without elevated eosinophils or FeNO; reduces exacerbations 50-70% |
If biologics fail or are unavailable, low-dose oral corticosteroids may be added (but consider significant side-effect burden).
Children 6-11 Years
A similar stepwise approach, but with age-specific dosing:
- Steps 1-2: Low-dose ICS (daily or as needed with SABA)
- Step 3: Low-dose ICS-LABA or medium-dose ICS; MART with ICS-formoterol
- Step 4: Medium-dose ICS-LABA; MART with medium-dose ICS-formoterol
- Step 5: High-dose ICS-LABA + refer for phenotypic assessment; add-on biologic therapy
Non-Pharmacological Strategies (At All Steps)
- Smoking cessation
- Physical activity and pulmonary rehabilitation
- Weight reduction (if overweight/obese)
- Vaccinations (influenza, pneumococcal)
- Avoidance of identified triggers (allergens, occupational exposures)
- Allergen immunotherapy (e.g., house dust mite sublingual immunotherapy) - consider if sensitized and not well-controlled on stable therapy with FEV1 >70% predicted
Asthma Attacks / Exacerbations
Acute management:
- Start short-acting beta-2 agonist (SABA) up to every 20 min in urgent care
- Oral corticosteroids:
- Adults: prednisolone 40-50 mg each morning for 5-7 days
- Children: prednisolone 1-2 mg/kg/day (max 40 mg) for 3-5 days
- Titrate oxygen to maintain saturation 93-95% in adults; ≥94% in children 6-12 years
- Do NOT routinely do chest X-ray, blood gases, or prescribe antibiotics
- Do NOT use sedatives
- Monitor closely; transfer to higher-level care if no improvement after 1 hour
Key Assessment at Every Visit
At each visit, assess and address:
- Symptom control and modifiable risk factors
- Inhaler technique and adherence (poor technique/adherence causes poor control in up to 50% of patients)
- Comorbidities (allergic rhinitis, GERD, obesity, obstructive sleep apnea)
- Lung function
- Patient goals and satisfaction
Sources:
- Harrison's Principles of Internal Medicine 22E (2025) - Asthma chapter, p. 2270
- Murray & Nadel's Textbook of Respiratory Medicine - Table 62.3, p. 1447
- GINA 2025 Summary Guide
This is a shared conversation. Sign in to Orris to start your own chat.